W33.F BioVersys AG
- Market cap
- EUR 142M
- P/E
- -
- P/B
- 2.93x
- ROE
- -36.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is W33.F undervalued?
Graham numberThe Graham number of BioVersys AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioVersys AG fundamental analysis
No fundamental analysis for BioVersys AG yet.
BioVersys AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioVersys AG
BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S. aureus; and BV500 for non-tuberculous mycobacteria infections. It has a researc…
Full company profileBioVersys AG financial statements
BioVersys AG annual financial statements (CHF; K = thousand, M = million, B = billion, T = trillion)
| Item | 2024 | 2025 |
|---|---|---|
| Income Statement | ||
| Revenue | 0.00 | 800K |
| Gross Profit | -3.95M | -3.09M |
| Operating Income | -18.7M | -20.0M |
| EBITDA | -17.4M | -20.4M |
| Net Income | -18.7M | -21.8M |
| EPS | -3.16 | -3.73 |
| Balance Sheet | ||
| Total Assets | 35.0M | 90.6M |
| Total Liabilities | 24.3M | 30.8M |
| Shareholders' Equity | 10.7M | 59.8M |
| Cash & Short-term Investments | 26.6M | 82.5M |
| Cash Flow | ||
| Operating Cash Flow | -15.6M | -21.9M |
| Capital Expenditure | 38.0K | 216K |
| Free Cash Flow | -15.6M | -22.2M |
| Ratios | ||
| ROE | -175.2% | -36.5% |
| ROA | -53.6% | -24.1% |
| Net Profit Margin | - | -2,728.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BioVersys AG dividends
BioVersys AG has not paid dividends in the last 2 fiscal years.
Who owns BioVersys AG
- Insiders 33.71%
- Institutions 13.12%
- Public & others 53.16%
- Shares outstanding 5.85M
- Free float 3.87M
BioVersys AG company profile
- Company name
- BioVersys AG
- Ticker
- W33.F
- ISIN
- CH0210362643
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 38
- Fiscal year end
- December
- Address
- Hochbergerstrasse 60c, Basel, Switzerland, 4057
- Phone
- 41 61 551 51 20
- Website
- bioversys.com
About BioVersys AG
BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S. aureus; and BV500 for non-tuberculous mycobacteria infections. It has a research and license option agreement with Shionogi & Co., Ltd. to develop ansamycin leads from the BV500 program into clinical candidates. The company was founded in 2008 and is based in Basel, Switzerland.
BioVersys AG management
10- Dr. Marc GitzingerCEO, Co-founder & Director · born 1981
- Mr. Hernan Santiago Levett CPAChief Financial Officer · born 1975
- Dr. Daniel RitzChief Scientific Officer · born 1964
- Ms. Anca CighiHead of Investor Relations & Communications
- Ms. Fiona Gao EMBA, L.L.M.Head of Legal
- Mr. Philipp SchmidHead of Finance
- Dr. Jonathan James ButcherHead of Business Development & Alliance Management
- Dr. Glenn E. DaleChief Development Officer · born 1963
- Dr. Jurgen JagerHead of Chemistry, Manufacturing & Controls
- Dr. Alessia MichelottiHead of Chemistry